Sort
10,766 grants matching “checkpoint inhibitor”
Leveraging Vulnerabilities Induced by STING Activation in Pancreatic Cancer
$572,887Timothy R Donahue · University Of California Los Angeles · R01 · FY2025 · CA
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma
$572,667Albert Koong · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
The Role of HIF2 in Pancreatic Ductal Adenocarcinoma
$572,667Cullen Mitsuo Taniguchi · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Predictive biomarker of BET bromodomain inhibitor in Small cell lung cancer
$572,509Haobin Chen · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
$572,502Gerardo Guillermo Mackenzie · University Of California At Davis · R01 · FY2025 · CA
Kinetic Assembly of Polymer-mRNA Nanoparticles Targets Circulating Monocytes to Enhance Cancer Immunotherapy
$572,485Hai-Quan Mao · Johns Hopkins University · R01 · FY2025 · CA
Harnessing TNFa Signaling To Improve Therapeutic Response In Pancreatic Cancer
$572,447Kian H Lim · Washington University · R01 · FY2024 · CA
Cell type-directed Tim-3 targeting in melanoma
$572,297Steven Russell Barthel · Brigham And Women'S Hospital · R01 · FY2023 · CA
Immunotherapeutic responses to neoantigens in head and neck cancer
$572,257Ravindra Uppaluri · Dana-Farber Cancer Inst · R01 · FY2022 · DE
Improving Glioma Immunotherapy Efficacy by Regulating Tumor Inflammation
$571,835Behnam Badie · Beckman Research Institute/City Of Hope · R01 · FY2025 · NS
Engineering immunotherapeutic probiotics to mitigate irAE
$571,668Tal Danino · Columbia Univ New York Morningside · U01 · FY2024 · CA
Dissecting Molecular Mechanisms of Tumor-Induced Myeloid-Mediated Immune Suppression in Triple-Negative Breast Cancer
$571,496Jianmin Zhang · University Of Toledo Health Sci Campus · R01 · FY2024 · CA
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma
$571,444Anna C Sorace · University Of Alabama At Birmingham · R01 · FY2023 · CA
Utilization of Immuno-PET to detect response and guide novel oHSV-based therapy for glioma
$571,444Anna C Sorace · University Of Alabama At Birmingham · R01 · FY2025 · CA
NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance
$571,380Stephen H Safe · Texas A&M University · R01 · FY2025 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$571,214Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2022 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$571,214Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · CA
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy
$571,193T.-C. Wu · Johns Hopkins University · R01 · FY2022 · CA
Overcoming Immunotherapy Resistance Through Opioid Antagonism in Head and Neck Cancer
$571,177Nicole N Scheff · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · DE
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
$571,136Brendan D Curti · Providence Portland Medical Center · R01 · FY2024 · CA
Molecular Targeting of Diffuse Large B-cell Lymphoma
$571,087Ari M. Melnick · Weill Medical Coll Of Cornell Univ · R01 · FY2012 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$571,062Nicholas C Denko · Ohio State University · R01 · FY2022 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$571,062Nicholas C Denko · Ohio State University · R01 · FY2023 · CA
Identifying and targeting neoantigens in aggressive salivary carcinomas
$570,903Luc Gordon Trang Morris · Sloan-Kettering Inst Can Research · R01 · FY2018 · DE
Dual action immunostimulatory nanoparticles for treatment of aggressive cancers
$570,868Efstathios Karathanasis · Case Western Reserve University · R01 · FY2024 · CA